应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02196 复星医药
休市中 08-23 16:08:27
12.260
-0.180
-1.45%
最高
12.480
最低
12.200
成交量
363.55万
今开
12.440
昨收
12.440
日振幅
2.25%
总市值
327.64亿
流通市值
67.68亿
总股本
26.72亿
成交额
4,471万
换手率
0.66%
流通股本
5.52亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
复星医药(02196.HK)落实每股24.6元私有化复宏汉霖(02696.HK)
阿斯达克财经 · 27分钟前
复星医药(02196.HK)落实每股24.6元私有化复宏汉霖(02696.HK)
二季度净利大跌88.4%!舍得酒业,如何突破瓶颈?
市场资讯 · 08-23 10:25
二季度净利大跌88.4%!舍得酒业,如何突破瓶颈?
赛分科技客户入股后销售额激增,业绩增长持续性遭问询|科创板IPO
时代财经 · 08-21
赛分科技客户入股后销售额激增,业绩增长持续性遭问询|科创板IPO
复星医药: 在创新研发推进过程中,公司持续动态评估管线的市场价值
证券之星 · 08-21
复星医药: 在创新研发推进过程中,公司持续动态评估管线的市场价值
复星医药(02196)为控股子公司提供担保
智通财经 · 08-21
复星医药(02196)为控股子公司提供担保
复星医药08月21日遭主力抛售351万元 环比增加108.93%
自选股智能写手 · 08-21
复星医药08月21日遭主力抛售351万元 环比增加108.93%
仿制药一致性评价概念盘中跳水,复星医药跌1.16%
自选股智能写手 · 08-20
仿制药一致性评价概念盘中跳水,复星医药跌1.16%
细胞免疫治疗概念盘中跳水,复星医药跌0.69%
自选股智能写手 · 08-20
细胞免疫治疗概念盘中跳水,复星医药跌0.69%
单抗概念盘中跳水,复星医药跌0.60%
自选股智能写手 · 08-20
单抗概念盘中跳水,复星医药跌0.60%
专访复星医药全球研发中心CEO王兴利:医药格局重塑时代,本土药企如何追赶MNC?
21财经网 · 08-20
专访复星医药全球研发中心CEO王兴利:医药格局重塑时代,本土药企如何追赶MNC?
新质生产力引领 复星医药与未磁科技战略合作推动量子磁场传感技术高质量发展
大众证券报 · 08-19
新质生产力引领 复星医药与未磁科技战略合作推动量子磁场传感技术高质量发展
注意!复星医药将于9月27日召开股东大会
每日经济新闻 · 08-19
注意!复星医药将于9月27日召开股东大会
复星医药(02196)拟为控股子公司汉霖制药申请的3000万元的授信额度提供担保
智通财经 · 08-16
复星医药(02196)拟为控股子公司汉霖制药申请的3000万元的授信额度提供担保
Revance以9.24亿美元被收购!复星医药(600196.SH)在中国独家商业化其明星肉毒素产品
智通财经 · 08-16
Revance以9.24亿美元被收购!复星医药(600196.SH)在中国独家商业化其明星肉毒素产品
医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强
金吾财讯 · 08-16
医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强
据报复星医药(02196.HK)等成立生物技术合伙企业 出资额100万元人币
阿斯达克财经 · 08-16
据报复星医药(02196.HK)等成立生物技术合伙企业 出资额100万元人币
减肥药概念盘中跳水,复星医药跌0.86%
自选股智能写手 · 08-16
减肥药概念盘中跳水,复星医药跌0.86%
北向资金8月15日净买入复星医药17.60万股 连续3日增持
自选股智能写手 · 08-16
北向资金8月15日净买入复星医药17.60万股 连续3日增持
8月15日复星医药现1笔大宗交易 机构净卖出2776.19万元
证券之星 · 08-15
8月15日复星医药现1笔大宗交易 机构净卖出2776.19万元
复星医药:斯鲁利单抗注射液上市许可申请获EMA收礼 目前处于审评阶段
每日经济新闻 · 08-15
复星医药:斯鲁利单抗注射液上市许可申请获EMA收礼 目前处于审评阶段
加载更多
公司概况
公司名称:
复星医药
所属市场:
SEHK
上市日期:
--
主营业务:
上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。
发行价格:
--
{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":12.26,"timestamp":1724400507030,"preClose":12.44,"halted":0,"volume":3635500,"delay":0,"floatShares":552000000,"shares":2672398711,"eps":0.97950125,"marketStatus":"休市中","marketStatusCode":7,"change":-0.18,"latestTime":"08-23 16:08:27","open":12.44,"high":12.48,"low":12.2,"amount":44711535,"amplitude":0.022508,"askPrice":12.26,"askSize":42500,"bidPrice":12.24,"bidSize":6500,"shortable":3,"etf":0,"ttmEps":0.8217208755135932,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1351526400000,"adjPreClose":12.44,"dividendRate":0.024133,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":1.3083919624207163,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":22.4,"timestamp":1724396400000,"preClose":22.39,"halted":0,"volume":5102954,"delay":0,"premium":"-50.05"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2462640827","title":"复星医药(02196.HK)落实每股24.6元私有化复宏汉霖(02696.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2462640827","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462640827?lang=zh_cn&edition=full","pubTime":"2024-08-25 16:41","pubTimestamp":1724575260,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布拟行使权利,以吸收合并方式将复宏汉霖(02696.HK) 私有化,每股H股现金价24.6元,涉及总额约32.25亿元;或每股H股发行1股香港存续股份。非上市股份每股现金注销价22.444794元人民币;或每股非上市股份发行1股中国存续股份。条件达成后 ,复宏汉霖将向联交所申请自愿撤销H股的上市地位。目前,要约人及其一致行动人士持有复宏汉霖股本65.23%。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-23 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1374732/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","02696","BK0060","BK0096","BK0175","BK1593","BK0183","BK1161","BK1191","BK0196","BK0187","02196","BK0028","BK0012","BK1515","BK0188","600196"],"gpt_icon":0},{"id":"2461586584","title":"二季度净利大跌88.4%!舍得酒业,如何突破瓶颈?","url":"https://stock-news.laohu8.com/highlight/detail?id=2461586584","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461586584?lang=zh_cn&edition=full","pubTime":"2024-08-23 10:25","pubTimestamp":1724379900,"startTime":"0","endTime":"0","summary":"2020年,舍得酒业分别实现营收和净利润27.04亿和5.079亿;到2023年,舍得酒业的营收已经增长至70.81亿,净利润则增长至17.71亿。为了推动销售,舍得酒业的销售费用仍保持在高位。截至8月22日收盘,舍得酒业股价报收45.29元,披露股价的次日股价大跌9.42%。再看机构持仓方面,一季度舍得酒业的机构持仓总数为32家,持股数量为1.588亿股,减少了1916万股,下降比例为5.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240823114446a1d5d8d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240823114446a1d5d8d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00656","BK1593","03189","BK1191","83189","02196","BK1610","BK1515","600196"],"gpt_icon":0},{"id":"2461874319","title":"赛分科技客户入股后销售额激增,业绩增长持续性遭问询|科创板IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2461874319","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461874319?lang=zh_cn&edition=full","pubTime":"2024-08-21 20:22","pubTimestamp":1724242955,"startTime":"0","endTime":"0","summary":"本文来源:时代商学院 作者:彭晨雨 来源|时代投研作者|彭晨雨编辑|孙一鸣客户入股后销售额激增,靠自家股东带来的收入增长能否持续?上交所官网显示,8月9日,苏州赛分科技股份有限公司(下称“赛分科技”)正式提交注册,拟登陆科创板。时代投研研究...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OFNQie9AcZf471cCmyzuHat317K7zrYLYO30MU_x5I5VUAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OFNQie9AcZf471cCmyzuHat317K7zrYLYO30MU_x5I5VUAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240821A08XRP00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240821A08XRP00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2461472849","title":"复星医药:\n在创新研发推进过程中,公司持续动态评估管线的市场价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2461472849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461472849?lang=zh_cn&edition=full","pubTime":"2024-08-21 19:01","pubTimestamp":1724238083,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药(600196)08月21日在投资者关系平台上答复投资者关心的问题。投资者:请介绍一下从Palatin公司授权的“女伟哥”bremelantide临床进展情况?复星医药董秘:投资者您好!在创新研发推进过程中,公司持续动态评估管线的市场价值。基于流行病学调研、临床需求差异等综合因素,已决策终止该项目。感谢您对公司的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100034039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0187","BK0028","BK1593","BK0196","BK0060","BK0188","02196","BK1191","BK0239","BK0183","BK1515","BK0012","600196","BK0096"],"gpt_icon":0},{"id":"2461527845","title":"复星医药(02196)为控股子公司提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2461527845","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461527845?lang=zh_cn&edition=full","pubTime":"2024-08-21 18:29","pubTimestamp":1724236141,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,公司拟为控股子公司朝晖药业向广发银行申请的本金不超过人民币2000万元的融资项下债务提供最高额连带责任保证担保;控股子公司北京卫驰拟为其控股子公司北京北铃向北京银行申请的人民币500万元贷款提供连带责任保证担保;公司、控股子公司复星健康拟为共同向华美银行申请的等值1500万美元共享授信额度项下债务互负连带清偿责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1167799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1515","BK0196","BK0239","BK0096","BK1593","BK0028","BK0175","BK1191","BK0060","02196","600196","BK0188","BK0187","BK0183"],"gpt_icon":0},{"id":"2461819742","title":"复星医药08月21日遭主力抛售351万元 环比增加108.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461819742","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461819742?lang=zh_cn&edition=full","pubTime":"2024-08-21 16:16","pubTimestamp":1724228186,"startTime":"0","endTime":"0","summary":"08月21日, 复星医药股价跌2.00%,报收12.72元,成交金额3083万元,换手率0.44%,振幅2.31%,量比1.57。复星医药今日主力资金净流出351万元,连续3日净流出,上一交易日主力净流出168万元,今日环比增加108.93%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为36.36%,平均跌幅为1.70%。该股近5个交易日下跌2.45%,主力资金累计净流出676万元;近20日主力资金累计净流入95万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408211617269f413970&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408211617269f413970&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","BK1515","02196"],"gpt_icon":0},{"id":"2460478045","title":"仿制药一致性评价概念盘中跳水,复星医药跌1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460478045","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460478045?lang=zh_cn&edition=full","pubTime":"2024-08-20 13:10","pubTimestamp":1724130612,"startTime":"0","endTime":"0","summary":"08月20日,仿制药一致性评价概念盘中跳水,截至13点10分,仿制药一致性评价概念整体指数下跌2.01%,报845.580点。从个股上来看,该概念的成分股中,复星医药跌1.16%,华海药业、京新药业、福元医药跌幅居前。从资金上来看,截止发稿,仿制药一致性评价概念主力净流入为-3.55亿,其中海辰药业受到资金热捧,主力净流入1119.09万;拉长时间线来看,该板块近20日主力资金净流入-38.27亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820131012af97804a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820131012af97804a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1515","600196","BK1593"],"gpt_icon":0},{"id":"2460238016","title":"细胞免疫治疗概念盘中跳水,复星医药跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460238016","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460238016?lang=zh_cn&edition=full","pubTime":"2024-08-20 10:19","pubTimestamp":1724120379,"startTime":"0","endTime":"0","summary":"08月20日,细胞免疫治疗概念盘中跳水,截至10点19分,细胞免疫治疗概念整体指数下跌1.04%,报671.070点。从个股上来看,该概念的成分股中,复星医药跌0.69%,ST八菱、东北制药、国际医学跌幅居前。从资金上来看,截止发稿,细胞免疫治疗概念主力净流入为-8294.94万,其中达安基因受到资金热捧,主力净流入5986.73万;拉长时间线来看,该板块近20日主力资金净流入-31.51亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820101939af977faa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820101939af977faa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1593","600196","BK1515","BK1191","BK1574","02196","06978"],"gpt_icon":0},{"id":"2460501634","title":"单抗概念盘中跳水,复星医药跌0.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460501634","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460501634?lang=zh_cn&edition=full","pubTime":"2024-08-20 10:06","pubTimestamp":1724119583,"startTime":"0","endTime":"0","summary":"08月20日,单抗概念盘中跳水,截至10点06分,单抗概念整体指数下跌1.01%,报1675.780点。从个股上来看,该概念的成分股中,复星医药跌0.60%,丽珠集团、桂林三金、百济神州-U跌幅居前。从资金上来看,截止发稿,单抗概念概念主力净流入为-1.03亿,其中康弘药业受到资金热捧,主力净流入930.21万;拉长时间线来看,该板块近20日主力资金净流入-19.98亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820100623aefedb6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820100623aefedb6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","600196","BK1191","BK1593"],"gpt_icon":0},{"id":"2460343016","title":"专访复星医药全球研发中心CEO王兴利:医药格局重塑时代,本土药企如何追赶MNC?","url":"https://stock-news.laohu8.com/highlight/detail?id=2460343016","media":"21财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460343016?lang=zh_cn&edition=full","pubTime":"2024-08-20 10:01","pubTimestamp":1724119279,"startTime":"0","endTime":"0","summary":"复星医药执行总裁、全球研发中心CEO王兴利在接受21世纪经济报道记者采访时表示,“老牌药企大部分都是仿制药出身,向创新药企转型需要一个迭代的过程。虽然时间可能会比较长,但我国本土药企中未来一定有能成长为国际化的跨国药企。”复星医药执行总裁、全球研发中心CEO王兴利选择合适的创新策略创新药的研发历来具有高风险高投入的特性。此外,复星医药还采用合作开发的模式,落地了中国首款CAR-T细胞治疗产品奕凯达。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201001299f3bdb71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408201001299f3bdb71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","09939","BK1604","LU0052750758.USD","IE00B5MMRT66.SGD","LU0072913022.USD","LU0067412154.USD","LU0231483743.USD","LU0106252389.USD","LU0048597586.USD","LU0359201885.HKD","LU0029875118.USD","LU0164865239.USD","LU0149721374.USD","LU0128522157.USD","BK1161","LU0449509016.USD","LU0449515922.USD","LU0320764755.SGD","BK1591","LU0348788117.USD","IE00B543WZ88.USD","LU0431992006.USD","IE0034224299.USD","LU0269904917.USD","LU0054450605.USD","LU0348816934.USD","LU0348805143.USD","IE0032431581.USD","LU0051755006.USD","LU0043850808.USD","LU0049853897.USD","LU0164880469.USD","600196","LU0359202008.SGD","LU0320764599.SGD","02196","BK1142","LU0211977185.USD","BK1574","BK1521","LU0251144936.SGD","LU0348735423.USD","BK1589","LU0315178854.USD","LU0348814723.USD","LU0359201612.USD","BK1233","LU0417516738.SGD","LU0048580855.USD"],"gpt_icon":1},{"id":"2460408439","title":"新质生产力引领 复星医药与未磁科技战略合作推动量子磁场传感技术高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2460408439","media":"大众证券报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460408439?lang=zh_cn&edition=full","pubTime":"2024-08-19 18:39","pubTimestamp":1724063940,"startTime":"0","endTime":"0","summary":"8月18日上午,国家重点研发计划“新型无液氦脑磁图系统研发”成果发布会暨未磁科技与复星医疗器械战略合作签约仪式在北京中关村国际创新中心成功举办。复星医疗器械与未磁科技正式启动战略合作,双方强强联合,有望推动量子磁场传感技术在脑科学研究和脑疾病诊疗中的应用与落地,成为重大脑疾病的精准诊疗整体解决方案,造福于广大患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408191840559f39980e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408191840559f39980e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","BK0183","BK0188","BK0196","00656","BK0012","BK0028","BK0239","02196","600196","BK0175","BK0187","BK0096"],"gpt_icon":0},{"id":"2460108128","title":"注意!复星医药将于9月27日召开股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2460108128","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460108128?lang=zh_cn&edition=full","pubTime":"2024-08-19 18:33","pubTimestamp":1724063603,"startTime":"0","endTime":"0","summary":"复星医药(SH600196,收盘价:23.29元)8月19日发布公告称,2024年9月27日13点30分,公司将在上海市虹许路358号上海天禧嘉福璞缇客酒店召开2024年第一次临时股东大会。本次股东大会将审议《关于选举非执行董事的议案》等议案,2024年9月23日收市后登记在册的股东可现场参会投票,或通过交易所投票系统行使表决权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202408193159487546.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202408193159487546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02196","BK1515","BK1593"],"gpt_icon":0},{"id":"2459291502","title":"复星医药(02196)拟为控股子公司汉霖制药申请的3000万元的授信额度提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2459291502","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459291502?lang=zh_cn&edition=full","pubTime":"2024-08-16 18:19","pubTimestamp":1723803579,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,2024年8月16日,公司控股子公司上海复宏汉霖生物制药有限公司(“汉霖制药”)与南京银行股份有限公司上海分行(“南京银行”)签订《最高债权额度合同》,汉霖制药向南京银行申请人民币3000万元的授信额度,授信额度项下债务发生期间为2024年6月21日至2025年6月20日。同日,控股子公司上海复宏汉霖生物技术股份有限公司(系汉霖制药的直接控股股东,以下简称“复宏汉霖”)与南京银行签订《最高额保证合同》,由复宏汉霖为汉霖制药于上述授信额度项下债务提供最高额连带责任保证担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK0239","BK0096","BK0183","01477","BK0028","BK0012","BK0188","BK1593","02196","BK1574","BK0187","BK0175","BK0196","BK1515","BK0060","BK1191"],"gpt_icon":0},{"id":"2459267799","title":"Revance以9.24亿美元被收购!复星医药(600196.SH)在中国独家商业化其明星肉毒素产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2459267799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459267799?lang=zh_cn&edition=full","pubTime":"2024-08-16 16:46","pubTimestamp":1723798008,"startTime":"0","endTime":"0","summary":"近日,一桩近10亿美元的收购案引发全球医美行业关注,8月13日,Crown Laboratories宣布将以9.24亿美元现金收购明星企业Revance Therapeutics, Inc. ,收购价为每股6.66美元,较2024年8月9日收盘价溢价89%,较60天VWAP溢价111%。作为一家新兴的生物科技公司,Revance凭借其创新的长效肉毒素产品DAXXIFY进入市场,引发了业界的广泛关注。在中国,复星医药早在2018年就已经和Revance达成合作,成为对方在中国的独家商业化合作伙伴。2022年9月,Revance作为美国第五款获批肉毒素上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0187","BK0239","BK1515","BK0196","BK0175","BK0183","BK0012","BK0060","BK0028","BK0188","BK1191","BK1593","600196","02196"],"gpt_icon":0},{"id":"2459250009","title":"医美概念股全线上扬 康哲药业(00867)涨9.47% 机构指医美类差异化上游厂商抢占市场能力更强","url":"https://stock-news.laohu8.com/highlight/detail?id=2459250009","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459250009?lang=zh_cn&edition=full","pubTime":"2024-08-16 14:26","pubTimestamp":1723789603,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股全线上扬,康哲药业(00867)涨9.47%,现代牙科(03600)涨4.93%,四环医药(00460)涨3.85%,医思健康(02138)涨2.86%,复星医药(02196)涨2.6%,瑞尔集团(06639)涨2.27%,昊海生物科技(06826)涨1.95%。开源证券研报指出,建议关注医美、化妆品行业的投资机会。医美类差异化上游厂商抢占市场能力更强,长期看“渗透率+国产化率+合规化程度”多维提升逻辑未变;化妆品行业温和复苏,机会与挑战并存,把握渠道、成分、品类等细分结构性机会且综合竞争力强劲的国货美妆品牌有望在变化中抢占市场。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/OWNjYzkwNTM4YzEwMTc4NjgyODQzNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWNjYzkwNTM4YzEwMTc4NjgyODQzNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942461","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","SG9999004220.SGD","BK1219","BK1593","06826","BK1100","06639","02138","BK1215","LU2488822045.USD","00460","BK1583","BK1600","BK1161","SG9999015978.USD","00867","BK1515","SG9999015945.SGD","BK1191","BK1511","SG9999015952.SGD","02196","03600"],"gpt_icon":0},{"id":"2459572702","title":"据报复星医药(02196.HK)等成立生物技术合伙企业 出资额100万元人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2459572702","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459572702?lang=zh_cn&edition=full","pubTime":"2024-08-16 13:54","pubTimestamp":1723787640,"startTime":"0","endTime":"0","summary":"据内媒报道,成都金诚安生物技术合伙企业(有限合伙)于近日成立,由复星医药(02196.HK) 旗下上海复星平耀投资管理及战兴泽共同持股,出资额为100万元人民币。新公司的经营范围包括技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广、企业管理咨询。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-16 12:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220221174702240_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220221174702240_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1372274&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0196","BK0012","BK0183","BK0239","BK0028","600196","BK0188","BK0175","02196","BK0096","BK1515","BK1593","BK0187","BK0060","BK1191"],"gpt_icon":0},{"id":"2459239660","title":"减肥药概念盘中跳水,复星医药跌0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459239660","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459239660?lang=zh_cn&edition=full","pubTime":"2024-08-16 09:36","pubTimestamp":1723772205,"startTime":"0","endTime":"0","summary":"08月16日,减肥药概念盘中跳水,截至09点36分,减肥药概念整体指数下跌0.54%,报789.920点。从个股上来看,该概念的成分股中,复星医药跌0.86%,信立泰、爱美客、诺泰生物跌幅居前。从资金上来看,截止发稿,减肥药概念主力净流入为489.45万,其中华东医药受到资金热捧,主力净流入593.87万;拉长时间线来看,该板块近20日主力资金净流入-18.37亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816093645968267e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816093645968267e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","600196","BK1515","BK1593"],"gpt_icon":0},{"id":"2459191236","title":"北向资金8月15日净买入复星医药17.60万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2459191236","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459191236?lang=zh_cn&edition=full","pubTime":"2024-08-16 09:30","pubTimestamp":1723771808,"startTime":"0","endTime":"0","summary":"8月15日, 北向资金增持复星医药17.60万股,连续3日增持。截止当日收盘,沪股通共持有复星医药5883.18万股,占流通股2.77%。沪股通增持金额前五个股分别为中国平安、招商银行、中信证券、贵州茅台、拓普集团。复星医药近5个交易日下跌1.60%,沪股通累计减持28.69万股;近20个交易日上涨0.78%,沪股通累计增持354.74万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816093034959cede5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816093034959cede5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","BK1593","02196","BK1515","BK1191"],"gpt_icon":0},{"id":"2459443891","title":"8月15日复星医药现1笔大宗交易 机构净卖出2776.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459443891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459443891?lang=zh_cn&edition=full","pubTime":"2024-08-15 17:20","pubTimestamp":1723713637,"startTime":"0","endTime":"0","summary":"证券之星消息,8月15日复星医药发生大宗交易,交易数据如下:大宗交易成交价格23.32元,成交119.05万股,成交金额2776.19万元,买方营业部为中国中金财富证券有限公司山东分公司,卖方营业部为机构专用。近三个月该股共发生1笔大宗交易,合计成交1.19万手。该股近期无解禁股上市。截至2024年8月15日收盘,复星医药报收于23.32元,下跌0.09%,换手率0.36%,成交量7.58万手,成交额1.77亿元。该股最近90天内共有1家机构给出评级,买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081500035533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","BK0175","BK0060","BK0188","BK0183","BK1191","02196","BK1515","600196","BK0012","BK0239","BK0096","BK1593","BK0028"],"gpt_icon":0},{"id":"2459466564","title":"复星医药:斯鲁利单抗注射液上市许可申请获EMA收礼 目前处于审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2459466564","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459466564?lang=zh_cn&edition=full","pubTime":"2024-08-15 17:04","pubTimestamp":1723712645,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:2023年3月23日,公司自主研发的抗PD-1单抗斯鲁利单抗(H药,中国商品名:汉斯状?)联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)的上市许可申请(MAA)获欧洲药品管理局(EMA)受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202408153157001210.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202408153157001210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0851},{"period":"1month","weight":-0.0538},{"period":"3month","weight":-0.0136},{"period":"6month","weight":-0.1275},{"period":"1year","weight":-0.3298},{"period":"ytd","weight":-0.2619}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.049472},{"month":2,"riseRate":0.75,"avgChangeRate":0.030189},{"month":3,"riseRate":0.666667,"avgChangeRate":0.053895},{"month":4,"riseRate":0.416667,"avgChangeRate":0.038772},{"month":5,"riseRate":0.416667,"avgChangeRate":0.023544},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.030979},{"month":7,"riseRate":0.583333,"avgChangeRate":0.016786},{"month":8,"riseRate":0.25,"avgChangeRate":-0.057622},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.025952},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035539},{"month":11,"riseRate":0.5,"avgChangeRate":0.05286},{"month":12,"riseRate":0.5,"avgChangeRate":0.024501}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}